Advanced search×

Benefits of interferon-β and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: A multicenter study.

Kazuya K Motomura, Atsushi A Natsume, Yugo Y Kishida, Hiroyuki H Higashi, Yutaka Y Kondo, Yoko Y Nakasu, Tatsuya T Abe, Hiroki H Namba, Kenji K Wakai, and Toshihiko T Wakabayashi

Cancer 117(8):1721-30 (2011) PMID 21061328

The aim of the current study was to catalog genomic and epigenomic abnormalities in newly diagnosed glioblastoma patients and determine the correlation among clinical, genetic, and epigenetic profiles and clinical outcome.

DOI: 10.1002/cncr.25637
Version: za2963e q8za8 q8zbd q8zcc q8zd1 q8zef q8zfc q8zgd
Buy PDF

Similar articles you may find interesting…

  1. Health-related quality of life in elderly patients with newly diagnosed glioblastoma treated with short-course radiation therapy plus concom...
    Giuseppe Minniti, Claudia Scaringi, and Riccardo Maurizi Enrici

    Int J Radiat Oncol Biol Phys 86(2):285-91 (2013) PMID 23642624

    To describe the quality of life (QOL) in elderly patients with glioblastoma (GBM) treated with an abbreviated course of radiation therapy (RT; 40 Gy in 15 fractions) plus concomitant and adjuvant temozolomide (TMZ). Health-related QOL (HRQOL) was assessed by European...
    Buy PDF
  2. Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Re...
    Denise A Yardley, Roohi R Ismail-Khan, and Jane B Trepel

    J Clin Oncol (2013) PMID 23650416

    PURPOSEEntinostat is an oral isoform selective histone deacetylase inhibitor that targets resistance to hormonal therapies in estrogen receptor-positive (ER+) breast cancer. This randomized, placebo-controlled, phase II study evaluated entinostat combined with the aromatase inhibitor...
    Buy PDF
  3. Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent ...
    Lars Wagner, Brian Turpin, and James Geller

    Pediatr Blood Cancer (2013) PMID 23630159

    Reducing temozolomide from 150 to 100 mg/m(2) /day improved tolerability, and treatment with this lower temozolomide dose was feasible and convenient as outpatient therapy. Although responses were seen in Ewing sarcoma, the benefit of adding bevacizumab remains unclear. Pediatr Blood Cancer 2013;9...
    Buy PDF